Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Canadian notice of patent allowance for Imutec's Virulizin

March 30, 1998

Promising preliminary results obtained with Melacine/Intron A combination in stage IV melanoma

March 27, 1998

Cytogen halts autologous lymphocyte therapy program

March 27, 1998

Coulter completes patient enrollment in Bexxar phase III trial

March 25, 1998

Phase II ImmTher trial begins in pediatric cancer patients

March 19, 1998

Cel-Sci expands North American clinical trial for Multikine

March 18, 1998

Ribi ImmunoChem and Schering-Plough sign distribution agreement for Melacine

March 18, 1998

Techniclone to begin TNT clinical trials using unique delivery system

March 16, 1998

Genentech and DAKO establish development agreement for HER2 detection

March 13, 1998

Patient enrollment completed for phase I/II pancreatic cancer trial

March 13, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent
BioWorld Science
Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral...